Cargando…

Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry

OBJECTIVES: In tumorous impairment of CNS, cytological identification of the neoplastic cells in CSF frequently requires the use of ancillary techniques. Our methods are focused on identifying algorithms that increase the probability of identifying CSF malignant cells. MATERIALS AND METHODS: A total...

Descripción completa

Detalles Bibliográficos
Autores principales: Dušková, Jaroslava, Sobek, Ondřej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651389/
https://www.ncbi.nlm.nih.gov/pubmed/29075565
http://dx.doi.org/10.1002/brb3.805
_version_ 1783272882158174208
author Dušková, Jaroslava
Sobek, Ondřej
author_facet Dušková, Jaroslava
Sobek, Ondřej
author_sort Dušková, Jaroslava
collection PubMed
description OBJECTIVES: In tumorous impairment of CNS, cytological identification of the neoplastic cells in CSF frequently requires the use of ancillary techniques. Our methods are focused on identifying algorithms that increase the probability of identifying CSF malignant cells. MATERIALS AND METHODS: A total of 1.272 CSF samples from patients with tumorous infiltration of CNS of nonhematologic origin along with 721 samples from patients with hematologic malignancies were analyzed in a complex setting including cytological and immunocytochemical investigations. RESULTS AND DISCUSSION: In CSF diagnostics we are aware of the limited amount of sample combined frequently with neoplastic oligocytosis. Provided atypical, potentially malignant cells in CSF are found, further investigation(s) should maximize the probability of their identification—an appropriate cytological staining and immunocytochemical panel is to be applied. (i) In cases of known recent malignancy: immunoprofile of the recent neoplasm has been considered in immunocytochemical panel. (ii) In patients with a history of malignancy: The propensity to develop a new different malignancy must be taken into account. (iii) Atypical cells found in the CSF of a patient with a negative history of malignancy: Considering the most frequent clinically silent malignancies, stepwise immunocytochemistry is employed. Three milliliter of initial CSF sample represents the absolute minimum to start with. CONCLUSIONS: The steps of the laboratory activity targeted on malignancy in the CSF detection can be expected as follows: (i) The sample will be divided for both nonmorphology and cytopathology investigations. (ii) Basic stainings will triage the samples into those with no suspicion of malignancy and the remaining ones. (iii) Special stainings and stepwise immunocytochemistry will be performed in parallel with the nonmorphology investigations.
format Online
Article
Text
id pubmed-5651389
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56513892017-10-26 Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry Dušková, Jaroslava Sobek, Ondřej Brain Behav Original Research OBJECTIVES: In tumorous impairment of CNS, cytological identification of the neoplastic cells in CSF frequently requires the use of ancillary techniques. Our methods are focused on identifying algorithms that increase the probability of identifying CSF malignant cells. MATERIALS AND METHODS: A total of 1.272 CSF samples from patients with tumorous infiltration of CNS of nonhematologic origin along with 721 samples from patients with hematologic malignancies were analyzed in a complex setting including cytological and immunocytochemical investigations. RESULTS AND DISCUSSION: In CSF diagnostics we are aware of the limited amount of sample combined frequently with neoplastic oligocytosis. Provided atypical, potentially malignant cells in CSF are found, further investigation(s) should maximize the probability of their identification—an appropriate cytological staining and immunocytochemical panel is to be applied. (i) In cases of known recent malignancy: immunoprofile of the recent neoplasm has been considered in immunocytochemical panel. (ii) In patients with a history of malignancy: The propensity to develop a new different malignancy must be taken into account. (iii) Atypical cells found in the CSF of a patient with a negative history of malignancy: Considering the most frequent clinically silent malignancies, stepwise immunocytochemistry is employed. Three milliliter of initial CSF sample represents the absolute minimum to start with. CONCLUSIONS: The steps of the laboratory activity targeted on malignancy in the CSF detection can be expected as follows: (i) The sample will be divided for both nonmorphology and cytopathology investigations. (ii) Basic stainings will triage the samples into those with no suspicion of malignancy and the remaining ones. (iii) Special stainings and stepwise immunocytochemistry will be performed in parallel with the nonmorphology investigations. John Wiley and Sons Inc. 2017-08-31 /pmc/articles/PMC5651389/ /pubmed/29075565 http://dx.doi.org/10.1002/brb3.805 Text en © 2017 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Dušková, Jaroslava
Sobek, Ondřej
Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry
title Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry
title_full Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry
title_fullStr Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry
title_full_unstemmed Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry
title_short Assisting the neurologist in diagnosis of CNS malignancies ‐ Current Possibilities and Limits of Cerebrospinal Fluid Cytology and Immunocytochemistry
title_sort assisting the neurologist in diagnosis of cns malignancies ‐ current possibilities and limits of cerebrospinal fluid cytology and immunocytochemistry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651389/
https://www.ncbi.nlm.nih.gov/pubmed/29075565
http://dx.doi.org/10.1002/brb3.805
work_keys_str_mv AT duskovajaroslava assistingtheneurologistindiagnosisofcnsmalignanciescurrentpossibilitiesandlimitsofcerebrospinalfluidcytologyandimmunocytochemistry
AT sobekondrej assistingtheneurologistindiagnosisofcnsmalignanciescurrentpossibilitiesandlimitsofcerebrospinalfluidcytologyandimmunocytochemistry